It was about four years ago when I started telling folks to buy Canadian cannabis stocks. We know cannabis will be fully legal in Canada this year, explains Jeff Siegel, editor of Energy & Capital.
The cannabis market in the United States today is very similar to the cannabis market we saw in Canada just four years ago. Although the plant was still federally illegal back then and there were plenty of prohibitionists pushing back against legalization, we knew momentum for legalization was strong.
The good news is that there’s now another chance to make a ton of money in the cannabis space — because everything that unfolded in Canada over the past four years is now unfolding in the United States.
In less than five years, the federal prohibition on cannabis will be lifted in the U.S., and a handful of U.S. cannabis players will be first in line to reap the rewards.
One company in particular that’s really capitalizing on the growth of the cannabis market in the U.S. is MariMed Advisors (MRMD). The firm has its hands in everything from cultivation to dispensaries, and it has the greatest exposure to the U.S. market of any U.S. cannabis player.
The company has developed and manages eight facilities in Rhode Island, Delaware, Illinois, and Nevada, with five new facilities under development in Massachusetts and Maryland.
MariMed’s financials are solid, too, unlike a lot of other U.S. cannabis players in the market. For FY 2017, MariMed saw $6.1 million in revenue, compared to $3.5 million in 2016. Assets also grew from $8.6 million in 2016 to $32.2 million in 2017.
One thing that makes MariMed particularly valuable is that, unlike a lot of other U.S. cannabis players in the market, it has had no problem raising capital without having to dilute shareholders. This is of immense value and makes MariMed a solid play for investors looking to capitalize on the rapid development of the U.S. cannabis market.
Bottom line: If you’re looking to get some exposure to the U.S. cannabis market, which is already making us a boatload of cash, MariMed is a solid play.
